Key Insights:
- The article highlights significant progress in addressing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) since 1980, including the approval of the first drug for metabolic dysfunction-associated steatohepatitis (MASH).
- The shift from nonalcoholic fatty liver disease (NAFLD) to MASLD aims to better capture the disease’s metabolic origins and guide future research and treatment strategies.
- The article calls for multidisciplinary care, advanced pharmacological and behavioral research, and policy changes to improve MASLD management, emphasizing education, health system preparedness, and policy support.
Substantial progress has been made in the MASLD field, but ongoing efforts are needed to optimize care, advance research, and address health disparities. Multidisciplinary approaches and supportive policies are crucial to reducing the burden of MASLD and MASH by 2030.